Literature DB >> 28341730

Combination of ibrutinib and chemotherapy produced a durable remission in multiply relapsed diffuse large B-cell lymphoma leg type with mutant MYD88 and wildtype CD79.

Andrew L Deng1, Yu Ri Kim1,2, Emily A Lichtenstein1, Owen A O'Connor1, Changchun Deng3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28341730      PMCID： PMC5566054          DOI： 10.3324/haematol.2016.161893

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  8 in total

1.  Oncogenically active MYD88 mutations in human lymphoma.

Authors:  Vu N Ngo; Ryan M Young; Roland Schmitz; Sameer Jhavar; Wenming Xiao; Kian-Huat Lim; Holger Kohlhammer; Weihong Xu; Yandan Yang; Hong Zhao; Arthur L Shaffer; Paul Romesser; George Wright; John Powell; Andreas Rosenwald; Hans Konrad Muller-Hermelink; German Ott; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; J R Cook; Denny D Weisenburger; Wing C Chan; Louis M Staudt
Journal:  Nature       Date:  2010-12-22       Impact factor: 49.962

2.  MYD88 Mutations and Response to Ibrutinib in Waldenström's Macroglobulinemia.

Authors:  Steven P Treon; Lian Xu; Zachary Hunter
Journal:  N Engl J Med       Date:  2015-08-06       Impact factor: 91.245

3.  Nuclear factor-κB pathway-activating gene aberrancies in primary cutaneous large B-cell lymphoma, leg type.

Authors:  Lianne Koens; Willem H Zoutman; Passorn Ngarmlertsirichai; Grzegorz K Przybylski; Piotr Grabarczyk; Maarten H Vermeer; Rein Willemze; Patty M Jansen; Christian A Schmidt; Cornelis P Tensen
Journal:  J Invest Dermatol       Date:  2013-06-13       Impact factor: 8.551

4.  Ibrutinib monotherapy in relapsed/refractory CNS lymphoma: A retrospective case series.

Authors:  Kamal Chamoun; Sylvain Choquet; Eileen Boyle; Caroline Houillier; Delphine Larrieu-Ciron; Ahmad Al Jijakli; Vanessa Delrieu; Vincent Delwail; Franck Morschhauser; Khê Hoang-Xuan; Carole Soussain
Journal:  Neurology       Date:  2016-11-18       Impact factor: 9.910

5.  MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.

Authors:  Steven P Treon; Lian Xu; Guang Yang; Yangsheng Zhou; Xia Liu; Yang Cao; Patricia Sheehy; Robert J Manning; Christopher J Patterson; Christina Tripsas; Luca Arcaini; Geraldine S Pinkus; Scott J Rodig; Aliyah R Sohani; Nancy Lee Harris; Jason M Laramie; Donald A Skifter; Stephen E Lincoln; Zachary R Hunter
Journal:  N Engl J Med       Date:  2012-08-30       Impact factor: 91.245

6.  A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.

Authors:  Guang Yang; Yangsheng Zhou; Xia Liu; Lian Xu; Yang Cao; Robert J Manning; Christopher J Patterson; Sara J Buhrlage; Nathanael Gray; Yu-Tzu Tai; Kenneth C Anderson; Zachary R Hunter; Steven P Treon
Journal:  Blood       Date:  2013-07-08       Impact factor: 22.113

7.  Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.

Authors:  Wyndham H Wilson; Ryan M Young; Roland Schmitz; Yandan Yang; Stefania Pittaluga; George Wright; Chih-Jian Lih; P Mickey Williams; Arthur L Shaffer; John Gerecitano; Sven de Vos; Andre Goy; Vaishalee P Kenkre; Paul M Barr; Kristie A Blum; Andrei Shustov; Ranjana Advani; Nathan H Fowler; Julie M Vose; Rebecca L Elstrom; Thomas M Habermann; Jacqueline C Barrientos; Jesse McGreivy; Maria Fardis; Betty Y Chang; Fong Clow; Brian Munneke; Davina Moussa; Darrin M Beaupre; Louis M Staudt
Journal:  Nat Med       Date:  2015-07-20       Impact factor: 53.440

8.  High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites.

Authors:  W Kraan; H M Horlings; M van Keimpema; E J M Schilder-Tol; M E C M Oud; C Scheepstra; P M Kluin; M J Kersten; M Spaargaren; S T Pals
Journal:  Blood Cancer J       Date:  2013-09-06       Impact factor: 11.037
  8 in total
  3 in total

1.  Large B - Cell Lymphoma of the Leg - Unfavourable Course with Rituximab/Bendamustin.

Authors:  Uwe Wollina; Nadine Schmidt; Jacqueline Schönlebe; Aleksandra Vojvodic; Gesina Hansel; André Koch; Torello Lotti
Journal:  Open Access Maced J Med Sci       Date:  2019-06-30

Review 2.  Cytologic and Molecular Diagnostics for Vitreoretinal Lymphoma: Current Approaches and Emerging Single-Cell Analyses.

Authors:  Wei Jian Tan; Mona Meng Wang; Paola Ricciardi-Castagnoli; Anita Sook Yee Chan; Tong Seng Lim
Journal:  Front Mol Biosci       Date:  2021-01-11

3.  Molecular Mechanisms of Disease Progression in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type during Ibrutinib Therapy.

Authors:  Lucy C Fox; Costas K Yannakou; Georgina Ryland; Stephen Lade; Michael Dickinson; Belinda A Campbell; Henry Miles Prince
Journal:  Int J Mol Sci       Date:  2018-06-13       Impact factor: 5.923
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.